Do peptides work for erectile dysfunction?

One does, in a narrow sense. PT-141 (bremelanotide) acts on central melanocortin receptors and has an approved indication for hypoactive sexual desire disorder in premenopausal women, plus earlier trial data showing erectile responses in men. It targets desire and central arousal signalling rather than the blood flow mechanics that PDE5 inhibitors address. Most other peptides marketed for erectile dysfunction have little or no direct human evidence, and several are being sold on mechanisms that do not apply to erectile function at all.

Is PT-141 better than Viagra?

They are not competing on the same mechanism, so better depends entirely on the problem. PDE5 inhibitors like sildenafil work peripherally by preserving cGMP in penile smooth muscle, which improves the hydraulics of an erection once arousal is present. PT-141 works centrally at MC4R and influences the arousal signal itself. Response rates in the original male erectile dysfunction trials were meaningful but not superior to established PDE5 therapy, and the nausea rate was high. The population where a melanocortin agonist has a genuine theoretical advantage is people whose problem is desire rather than blood flow, or who do not respond to PDE5 inhibitors.

What dose of PT-141 is used in research?

The approved female indication uses 1.75 mg subcutaneously as needed, no more than once in 24 hours and no more than eight doses per month. Earlier male erectile dysfunction studies used intranasal and subcutaneous routes across a wider range, and the subcutaneous doses that produced consistent responses also produced the nausea and flushing that ended the intranasal programme. Nothing above the approved 1.75 mg single dose has a favourable evidence base, and higher amounts mainly increase side effects rather than response.

Does BPC-157 help erectile dysfunction?

There is no human evidence for it. The claim circulates because rodent studies have reported that BPC-157 counteracts erectile disturbance caused by certain drug models and involves nitric oxide system modulation, which is mechanistically adjacent to how PDE5 inhibitors work. That is a long distance from a demonstrated clinical effect in humans, and no controlled human trial of BPC-157 for erectile function exists. Anyone selling it on that basis is extrapolating from rat data.

Can peptides fix erectile dysfunction caused by low testosterone?

Not directly, and this is the most important diagnostic point on the page. Erectile dysfunction is frequently the first visible sign of something systemic: cardiovascular disease, diabetes, hypogonadism, sleep apnea, depression or medication side effects. If low testosterone is the driver, the fix is diagnosing and treating the hypogonadism, and kisspeptin is the only peptide in this space that acts upstream on that axis, still at an investigational stage. Layering a melanocortin agonist on top of an untreated endocrine or vascular problem masks a signal that is worth listening to.

What are the side effects of peptides used for erectile function?

For PT-141 the dominant effects are nausea (reported by roughly 40 percent of participants in the approval trials), flushing, headache and injection site reactions, plus transient blood pressure increases and small heart rate reductions in the hours after dosing. That transient pressor effect is why uncontrolled hypertension and known cardiovascular disease are contraindications. Melanotan II adds unwanted pigmentation, nausea and the melanocyte concerns that come with indiscriminate melanocortin receptor activation. Kisspeptin has been well tolerated in trials but has almost no long term safety data.

Peptides for Erectile Dysfunction: What the Evidence Actually Supports

Research use only. Erectile dysfunction is a medical condition and frequently an early marker of cardiovascular or endocrine disease. Nothing here is medical advice, no compound described is approved for erectile dysfunction in men, and self-treating a symptom that warrants investigation is the main risk on this page. Consult a licensed healthcare provider.

Two Pathways Sold Under One Label

An erection is the end of a chain, and things marketed as peptides for erectile dysfunction intervene at very different points in it. Understanding which point a compound targets explains almost everything about whether it can plausibly help.

The peripheral half is the one most people know. Arousal signals travel down through the spinal cord, nitrergic nerves and endothelium release nitric oxide in the corpus cavernosum, nitric oxide raises cyclic GMP, cGMP relaxes smooth muscle, blood fills the sinusoids and venous outflow is compressed. Sildenafil and tadalafil work here by inhibiting the enzyme that degrades cGMP. They do not create arousal, they preserve the mechanical consequence of it, which is exactly why they fail when the upstream signal never arrives.

The central half is where peptides live. In the hypothalamus, particularly the paraventricular nucleus, melanocortin signalling at MC4R and dopaminergic and oxytocinergic projections shape sexual desire and the descending pro-erectile output. A melanocortin agonist reaching those receptors can initiate arousal signalling rather than amplify its downstream plumbing. That is a genuinely different mechanism, and it is the only reason peptides are in this conversation at all.

The framing that matters: if the problem is vascular or endothelial, a central peptide is aimed at the wrong layer. If the problem is desire and central arousal, a PDE5 inhibitor is aimed at the wrong layer. Most people never work out which one they have, which is why so much of this category disappoints.

PT-141 (Bremelanotide): The Only One With an Approval

PT-141 is a cyclic heptapeptide derived from melanotan II, developed after researchers noticed that melanotan II trial participants were reporting spontaneous erections as a side effect of a tanning compound. Chemists stripped the molecule back toward the melanocortin activity responsible for the sexual effect and away from the pigmentation activity, which is the entire origin story of this compound.

It acts as a non-selective melanocortin receptor agonist with the relevant action at MC4R in the hypothalamus. Because the effect is central, it does not require intact endothelial nitric oxide signalling to initiate a response, and it is not dependent on the same vascular machinery a PDE5 inhibitor needs.

What the Trials Showed

The male erectile dysfunction programme ran first. Intranasal bremelanotide produced measurable erectile responses in men, including in a subgroup who had responded poorly to sildenafil, which was the most interesting finding to come out of the work. That programme was halted over blood pressure increases seen with the intranasal route at the doses being used.

Development then moved to subcutaneous dosing and to female hypoactive sexual desire disorder, where the RECONNECT trials led to approval in 2019 for premenopausal women at 1.75 mg subcutaneously as needed. That is the only approved indication anywhere. Men buying PT-141 for erectile function are using a compound with real supporting data for a use it was never licensed for.

Parameters Used in the Approved Protocol

Dose: 1.75 mg subcutaneously, single use as needed
Frequency limit: No more than one dose per 24 hours, no more than 8 per month
Timing: Roughly 45 minutes before anticipated activity
Onset and duration: Effect builds over 1 to 2 hours, window measured in hours rather than days
Dominant side effect: Nausea, reported by around 40 percent of trial participants

The nausea figure deserves emphasis because it is the practical ceiling on this compound. It is dose related, it is the reason escalating past the approved amount rarely improves the experience, and it is why a meaningful share of people who try PT-141 do not continue. The full mechanistic and dosing picture is in the PT-141 peptide guide.

Kisspeptin: Working Further Upstream

Kisspeptin sits above the entire reproductive axis. It signals through KISS1R on GnRH neurons and is the permissive switch for GnRH release, which drives LH and FSH, which drives testosterone. That places it a level above anything else discussed here.

Imperial College London ran a series of studies administering kisspeptin-54 to men, including men with hypoactive sexual desire disorder. Functional imaging showed enhanced activity in limbic structures in response to sexual stimuli, and the work reported behavioural and self-reported changes alongside the hormonal effects. The signal is interesting and the trials were well designed, but the numbers were small and the administration in most of the work was intravenous infusion in a research setting.

That is the honest position on kisspeptin: a legitimate research target with early human data, and no established protocol, dose or safety record for the way it is sold in the research chemical market. It is the compound most worth watching in this space and the one most oversold relative to what has been demonstrated.

Melanotan II: The Accident That Started This

Melanotan II is where the melanocortin and sexual function link was first noticed, and it does produce erectile responses in men, including in trials specifically examining that effect. It is also a blunt instrument. It activates MC1R (pigmentation), MC3R and MC5R alongside MC4R, which means anyone taking it for sexual function is also getting tanning, appetite suppression and whatever else broad melanocortin agonism produces.

The side effect load is why PT-141 exists at all. Nausea, flushing, spontaneous and unwanted erections, darkening of existing moles and the unresolved question of what indiscriminate melanocyte stimulation does over time all sit on the melanotan II side of the comparison. Anyone drawn to it for erectile function is choosing the unrefined version of a compound that was already refined for exactly this purpose. The detail is in the melanotan II guide.

Compounds Sold for This With No Human Evidence

A large share of what is marketed as peptides for erectile dysfunction has nothing behind it for this indication. Being specific is more useful than a general warning.

BPC-157. Rodent work reports protection against drug induced erectile disturbance and involvement of nitric oxide system modulation. No human trial exists for this use. The general evidence picture is in the BPC-157 guide.
Growth hormone secretagogues. Ipamorelin, CJC-1295, sermorelin and MK-677 raise GH and IGF-1. Neither GH nor IGF-1 has a demonstrated role in treating erectile dysfunction, and the marketing here is a general vitality claim wearing a mechanism it does not have.
Oxytocin. Involved in orgasm and post-coital physiology, with no demonstrated effect on erectile function. It is an affiliative compound, not an arousal compound, and the evidence for the intranasal route is weak in general. See the oxytocin peptide guide.
Blends and proprietary sprays. Unlabelled combinations sold for sexual performance carry the dosing uncertainty of every component at once, and any effect they produce is usually attributable to a single known compound at an undisclosed amount.

The pattern is consistent across this category: a plausible mechanism from animal work gets presented as a clinical finding. The same gap between mechanism and demonstrated effect shows up whenever a compound is compared against pharmaceuticals, which is covered from the other direction in peptides versus steroids.

How Peptides Compare to PDE5 Inhibitors

PDE5 inhibitors are the reference standard for a reason. They have decades of safety data, response rates around 60 to 80 percent in general erectile dysfunction populations, oral dosing and a well characterised interaction profile. Any peptide is being measured against that.

Approach	Site of action	Targets	Evidence status
PDE5 inhibitors	Peripheral, penile smooth muscle	Erection mechanics	Approved, extensive data
PT-141	Central, hypothalamic MC4R	Desire and arousal signalling	Approved for female HSDD only
Kisspeptin	Central, upstream of GnRH	Reproductive axis and limbic response	Early human trials, investigational
Melanotan II	Central and peripheral melanocortin	Arousal plus pigmentation	Unapproved, poor selectivity
GH peptides	Pituitary GH release	Not erectile function	No evidence for this use

The one situation where the central approach has an argument is a PDE5 non-responder whose vascular function is intact, or someone whose primary complaint is desire rather than rigidity. Combining a melanocortin agonist with a PDE5 inhibitor has been studied and is not a casual stack, because both influence blood pressure and the interaction has not been characterised for unsupervised use.

The other thing worth saying plainly: erectile dysfunction correlates strongly enough with cardiovascular disease that it is treated clinically as an early warning sign, often preceding a cardiac event by several years. A compound that produces a result without addressing that is removing a symptom that was carrying information.

Side Effects and Who Should Not Experiment

PT-141

Nausea. The defining side effect, dose related, around 40 percent in trials, occasionally severe enough to stop use entirely.
Flushing and headache. Common, generally mild, resolving within the dosing window.
Transient blood pressure increase. A small rise in systolic and diastolic pressure with a compensatory heart rate reduction in the hours after dosing. This is the reason the intranasal male programme stopped.
Injection site reactions and darkening of skin or gums. Pigmentation effects appear with repeated dosing even at the improved selectivity.

Hard Contraindications

Uncontrolled hypertension or known cardiovascular disease. The pressor effect is the specific concern, and it is not theoretical.
Concurrent nitrates. Relevant to anyone also using or considering PDE5 inhibitors, where the interaction is dangerous.
Untreated underlying cause. Diabetes, hypogonadism, sleep apnea or medication effects should be diagnosed before anything is layered on top.

Class level monitoring guidance is in the peptide side effects guide, and the wider risk framing for research compounds is in are peptides safe. Sex-specific dosing considerations, which matter here because the only approved melanocortin indication is a female one, are covered in peptides for women.

Sourcing and Handling

PT-141 ships lyophilised and is stable enough in that state, but it is dosed in single milligram amounts where reconstitution arithmetic errors are large in relative terms. Reconstitute with bacteriostatic water down the vial wall, refrigerate immediately, and check the maths rather than eyeballing it. The procedure is in how to reconstitute peptides and the concentration calculator is here.

Verification matters more than usual with this category, because sexual performance products attract the least scrupulous end of the market and adulteration with unlabelled PDE5 inhibitors is a documented problem in that segment. A lot-matched Certificate of Analysis is the minimum, and the process for reading one is in how to buy peptides safely.

Where the Bureau sources these

Suppliers carrying the compounds above with lot-matched COA testing, per the 2026 vendor scorecard. Research use only, and none of these are approved for erectile dysfunction.

PT-141 at Pantheon PT-141 at Amino Club Kisspeptin at Amino Club

Long term temperature and shelf life guidance is in the peptide storage guide, which is relevant here because an as-needed compound sits in a fridge for weeks between uses rather than being consumed on a daily schedule.

Frequently Asked Questions

How long does PT-141 take to work?

The approved protocol has it dosed about 45 minutes ahead of anticipated activity, with the effect building over roughly one to two hours. It is slower to arrive than a PDE5 inhibitor and the window is measured in hours. Unlike tadalafil, it is not a compound that establishes a background state across days, so timing is part of using it at all.

Can PT-141 and sildenafil be combined?

Combination has been studied but it is not a casual stack. Both affect blood pressure through different mechanisms, PT-141 produces a transient pressor effect while PDE5 inhibitors are vasodilators, and the net cardiovascular result in an unsupervised setting is not well characterised. Anyone on nitrates should not be near a PDE5 inhibitor at all. This is a supervised question, not a self-experimentation one.

Does PT-141 work for men, or only women?

The male data exists and predates the female approval. Intranasal bremelanotide produced erectile responses in men in earlier trials, including in some sildenafil non-responders, and that programme was stopped over blood pressure rather than over lack of effect. Development then moved to the female indication where it succeeded. So the male evidence is real but incomplete, and there is no approved male protocol.

Is there a peptide that works like Viagra?

No, and the framing is the mistake. Nothing in the peptide category acts on phosphodiesterase or on the peripheral cGMP mechanism the way a PDE5 inhibitor does. The peptides with any evidence work centrally on desire and arousal signalling instead. Something advertised as a peptide alternative to sildenafil is either misdescribing its own mechanism or is not what the label says.

Should erectile dysfunction be investigated before trying anything?

Yes, and this is the single most useful line on this page. Erectile dysfunction is an independent predictor of cardiovascular events and often appears years before one. It is also a common presentation of diabetes, hypogonadism, thyroid disorders, sleep apnea, depression and a long list of medication effects. Suppressing the symptom with any compound while the cause goes unexamined trades a warning signal for a short term result.